<DOC>
	<DOCNO>NCT00244257</DOCNO>
	<brief_summary>This study design investigate safety single infusion GMA161 patient idiopathic thrombocytopenic purpura , well , way drug enters leave body . In addition , throughout study , platelet count blood cell number measure . NOTE : A decision make terminate study June 2008 due low enrollment .</brief_summary>
	<brief_title>Safety Study GMA161 Patients With Idiopathic Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Willing able provide write informed consent prior studyrelated procedure Chronic idiopathic thrombocytopenic purpura diagnose least 6 month A platelet count &lt; 100,000/mm^3 2 determination least 6 week apart , include 1 determination within 7 day prior initiate study treatment . Patients stable dose corticosteroid 2 week prior study entry platelet count &lt; 100,000/mm^3 may enrol Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 , life expectancy least 6 month Women pregnant lactate Women childbearing potential unless use medically acceptable contraceptive precaution use spermicide sexually inactive Women plan become pregnant within 6 month screen phase Evidence excessive bleeding require hospitalization within 6 week study entry red cell transfusion within 6 week study entry Absolute neutrophil count &lt; 2,000/mm^3 Total bilirubin &gt; 2 mg/dL alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 3 time upper limit normal range institutional laboratory Creatinine &gt; 2 mg/dL History druginduced thrombocytopenia , marrow failure syndrome , aplastic anemia myelodysplasia , thrombocytopenia related viral bacterial infection Elevated ( â‰¥ 1.5 time upper limit normal range ) prothrombin time ( PT ) partial thromboplastin time ( PTT ) ( relate lupus anticoagulant contact factor defect ) Evidence active bacterial infection viral infection Active hemolysis require red cell transfusion within 6 week study entry ( Patients evidence concurrent autoimmune hemolysis [ Evan 's Syndrome ] allow ) History clinically significant cardiac pulmonary disease History cancer , : basal cell skin cancer , squamous cell skin cancer previous chemotherapy treatment diseasefree carcinoma situ cervix , minimum 5 year time Screening HIV infection acute persistent hepatitis B C viral infection ( characterize positive hepatitis B surface antigen ( HBsAg ) , positive antihepatitis C virus [ HCV ] polymerase chain reaction [ PCR ] assay HCV ) History concurrent autoimmune disorder require systemic treatment involvement organ system cytopenias thyroid disease Treatment cyclophosphamide , vincristine , rituximab , monoclonal antibody within 12 week study infusion Treatment intravenous immunoglobulin ( IVIg ) within 2 week study drug infusion Rh ( D ) immune globulin intravenous within 4 week study drug infusion Treatment agent , IVIg corticosteroid , ITP within 4 week study entry . The dose level corticosteroid may increase decrease within 2 week study entry Use investigational drug within 12 week Screening Other pathology might interfere assessment safety efficacy test article clinically significant , uncontrolled medical condition , Investigator 's opinion , might interfere assessment followup . Patients splenectomized within 2 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>idiopathic thrombocytopenia purpura</keyword>
</DOC>